Edgar Filing: NEOPROBE CORP - Form 8-K

NEOPROBE CORP Form 8-K August 24, 2011

### **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

August 17, 2011

#### NEOPROBE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 0-26520 31-1080091 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)

425 Metro Place North, Suite 300, Columbus, Ohio

(Address of principal executive offices)

43017

(Zip Code)

Registrant's telephone number, including area code (614) 793-7500

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: NEOPROBE CORP - Form 8-K

Item Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
 5.02 Compensatory Arrangements of Certain Officers.

On August 17, 2011, in connection with the closing of the transactions contemplated by the Asset Purchase Agreement, dated May 24, 2011, between Neoprobe Corporation (the "Company"), and Devicor Medical Products, Inc. ("Devicor"), Anthony K. Blair, Vice President, Manufacturing Operations, resigned his position with the Company to become employed by Devicor.

2

# Edgar Filing: NEOPROBE CORP - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Neoprobe Corporation

Date: August 23, 2011 By: /s/ Brent L. Larson

Brent L. Larson, Senior Vice

President and

Chief Financial Officer

3